Watson Natasha, Grieu Fabienne, Morris Melinda, Harvey Jennet, Stewart Colin, Schofield Lyn, Goldblatt Jack, Iacopetta Barry
School of Surgery and Pathology M507, University of Western Australia, Nedlands 6009, Australia.
J Mol Diagn. 2007 Sep;9(4):472-8. doi: 10.2353/jmoldx.2007.060162. Epub 2007 Jul 25.
The aim of this study was to determine the frequency of microsatellite instability (MSI(+)) in tumors from a population-based series of young colorectal cancer patients and its correlation with the loss of expression of mismatch repair (MMR) proteins. The BAT-26 mononucleotide repeat was used to screen for MSI(+) in all colorectal cancers diagnosed in Western Australia throughout a 5-year period in patients <60 years of age. MSI(+) was found in 75 of 1003 (7.5%) cases, of which six contained a concomitant mutation in BRAF and were therefore excluded from further investigations as possible hereditary nonpolyposis colorectal cancer. Immunohistochemistry was used to evaluate expression of the four major MMR proteins (MLH1, MSH2, MSH6, and PMS2) in the remaining 69 MSI(+) tumors. Complete loss of MLH1 and PMS2 expression or of MSH2 and MSH6 expression was found in 35 (51%) and 17 (25%) cases, respectively, whereas other patterns of complete loss were observed in eight cases (12%). Eight tumors (12%) were initially recorded as showing normal expression, but on review seven were reclassified as having abnormal staining because of heterogeneous patterns of MMR loss. Three of these seven cases had previously been found to have germline mutations. Because of possible misinterpretation of heterogeneous immunohistochemistry staining for MMR protein loss, MSI testing is recommended as the initial screen for population-based detection of hereditary nonpolyposis colorectal cancer.
本研究的目的是确定基于人群的年轻结直肠癌患者系列肿瘤中微卫星不稳定性(MSI(+))的频率及其与错配修复(MMR)蛋白表达缺失的相关性。使用BAT-26单核苷酸重复序列对西澳大利亚州在5年期间诊断出的所有年龄<60岁的结直肠癌患者进行MSI(+)筛查。在1003例病例中的75例(7.5%)中发现了MSI(+),其中6例伴有BRAF突变,因此作为可能的遗传性非息肉病性结直肠癌被排除在进一步研究之外。采用免疫组织化学方法评估其余69例MSI(+)肿瘤中四种主要MMR蛋白(MLH1、MSH2、MSH6和PMS2)的表达。分别在35例(51%)和17例(25%)病例中发现MLH1和PMS2表达完全缺失或MSH2和MSH6表达完全缺失,而在8例(12%)病例中观察到其他完全缺失模式。8例肿瘤(12%)最初记录为表达正常,但复查时发现7例因MMR缺失的异质性模式而重新分类为染色异常。这7例病例中有3例先前已发现存在种系突变。由于对MMR蛋白缺失的异质性免疫组织化学染色可能存在误解,建议将MSI检测作为基于人群检测遗传性非息肉病性结直肠癌的初始筛查方法。